Recent developments of HDAC inhibitors: Emerging indications and novel molecules

The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials involving HDAC inhibitors, prompting us to further...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 87; no. 12; pp. 4577 - 4597
Main Authors Bondarev, Andrey D., Attwood, Misty M., Jonsson, Jörgen, Chubarev, Vladimir N., Tarasov, Vadim V., Schiöth, Helgi B.
Format Journal Article
LanguageEnglish
Published England 01.12.2021
Subjects
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
belinostat
epigenetics
HDAC inhibition
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylase Inhibitors - therapeutic use
HIV Infections - drug therapy
Humans
panobinostat
romidepsin
vorinostat
HDAC inhibition
belinostat
vorinostat
romidepsin
panobinostat
epigenetics
Online AccessGet full text

Cover

Abstract The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials involving HDAC inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 32 agents with HDAC‐inhibiting properties, of which 29 were found to interact with the HDAC enzymes as their primary therapeutic target. In this review, we provide an overview of the clinical drug development highlighting the recent advances and provide analysis of specific trials and, where applicable, chemical structures. We found haematologic neoplasms continue to represent the majority of clinical indications for this class of drugs; however, it is clear that there is an ongoing trend towards diversification. Therapies for non‐oncology indications including HIV infection, muscular dystrophies, inflammatory diseases as well as neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia and Friedreich's ataxia are achieving promising clinical progress. Combinatory regimens are proving to be useful to improve responsiveness among FDA‐approved agents; however, it often results in increased treatment‐related toxicities. This analysis suggests that the indication field is broadening through a high number of clinical trials while several fields of preclinical development are also promising.
AbstractList The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials involving HDAC inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 32 agents with HDAC-inhibiting properties, of which 29 were found to interact with the HDAC enzymes as their primary therapeutic target. In this review, we provide an overview of the clinical drug development highlighting the recent advances and provide analysis of specific trials and, where applicable, chemical structures. We found haematologic neoplasms continue to represent the majority of clinical indications for this class of drugs; however, it is clear that there is an ongoing trend towards diversification. Therapies for non-oncology indications including HIV infection, muscular dystrophies, inflammatory diseases as well as neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia and Friedreich's ataxia are achieving promising clinical progress. Combinatory regimens are proving to be useful to improve responsiveness among FDA-approved agents; however, it often results in increased treatment-related toxicities. This analysis suggests that the indication field is broadening through a high number of clinical trials while several fields of preclinical development are also promising.
The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials involving HDAC inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 32 agents with HDAC-inhibiting properties, of which 29 were found to interact with the HDAC enzymes as their primary therapeutic target. In this review, we provide an overview of the clinical drug development highlighting the recent advances and provide analysis of specific trials and, where applicable, chemical structures. We found haematologic neoplasms continue to represent the majority of clinical indications for this class of drugs; however, it is clear that there is an ongoing trend towards diversification. Therapies for non-oncology indications including HIV infection, muscular dystrophies, inflammatory diseases as well as neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia and Friedreich's ataxia are achieving promising clinical progress. Combinatory regimens are proving to be useful to improve responsiveness among FDA-approved agents; however, it often results in increased treatment-related toxicities. This analysis suggests that the indication field is broadening through a high number of clinical trials while several fields of preclinical development are also promising.The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials involving HDAC inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 32 agents with HDAC-inhibiting properties, of which 29 were found to interact with the HDAC enzymes as their primary therapeutic target. In this review, we provide an overview of the clinical drug development highlighting the recent advances and provide analysis of specific trials and, where applicable, chemical structures. We found haematologic neoplasms continue to represent the majority of clinical indications for this class of drugs; however, it is clear that there is an ongoing trend towards diversification. Therapies for non-oncology indications including HIV infection, muscular dystrophies, inflammatory diseases as well as neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia and Friedreich's ataxia are achieving promising clinical progress. Combinatory regimens are proving to be useful to improve responsiveness among FDA-approved agents; however, it often results in increased treatment-related toxicities. This analysis suggests that the indication field is broadening through a high number of clinical trials while several fields of preclinical development are also promising.
Author Jonsson, Jörgen
Schiöth, Helgi B.
Chubarev, Vladimir N.
Tarasov, Vadim V.
Bondarev, Andrey D.
Attwood, Misty M.
Author_xml – sequence: 1
  givenname: Andrey D.
  surname: Bondarev
  fullname: Bondarev, Andrey D.
  organization: Uppsala University
– sequence: 2
  givenname: Misty M.
  surname: Attwood
  fullname: Attwood, Misty M.
  organization: Uppsala University
– sequence: 3
  givenname: Jörgen
  surname: Jonsson
  fullname: Jonsson, Jörgen
  organization: Uppsala University
– sequence: 4
  givenname: Vladimir N.
  surname: Chubarev
  fullname: Chubarev, Vladimir N.
  organization: Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University
– sequence: 5
  givenname: Vadim V.
  surname: Tarasov
  fullname: Tarasov, Vadim V.
  organization: I. M. Sechenov First Moscow State Medical University
– sequence: 6
  givenname: Helgi B.
  orcidid: 0000-0001-7112-0921
  surname: Schiöth
  fullname: Schiöth, Helgi B.
  email: helgis@bmc.uu.se
  organization: I. M. Sechenov First Moscow State Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33971031$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-469673$$DView record from Swedish Publication Index
BookMark eNp9kU9L7DAUxYMoOo4u_ALSpYLVpmnSxt288S8IiqjbkKS38yJt0pe0Dn57o6MuHui9i1zC75zFOdto3ToLCO3h7BjHOVG6P8ZFVfE1NMGE0TTHOV1Hk4xkLKU5xVtoO4TnLMMEM7qJtgjhJc4InqC7e9Bgh6SGF2hd38U7JK5Jrs5m88TYv0aZwflwmpx34BfGLuJnbbQcjLMhkbZOrIvKpHMt6LGFsIM2GtkG2P18p-jx4vxhfpXe3F5ez2c3qS4Y4SnPG66LSpImbqlkqXRJc6bicN5oKlXBVFU0mGpWFqTIG6hVLmWVYcqlrskUHa18wxL6UYnem076V-GkEWfmaSacX4hxFAXjrCQRP1jhvXf_RgiD6EzQ0LbSghuDyGNMjBEad4r2P9FRdVB_O3-FFoHDFaC9C8FD843gTLwXImIh4qOQyJ78x2ozfKQ3eGna3xRL08Lrz9biz_xupXgDF1CcPw
CitedBy_id crossref_primary_10_1016_j_drudis_2024_104193
crossref_primary_10_3390_ijms252212010
crossref_primary_10_3390_cancers15010138
crossref_primary_10_1002_ardp_202400437
crossref_primary_10_32604_or_2022_026913
crossref_primary_10_1002_advs_202408845
crossref_primary_10_1038_s41380_023_02208_7
crossref_primary_10_3390_ijms241612588
crossref_primary_10_1007_s00726_023_03249_6
crossref_primary_10_1016_j_cclet_2023_108359
crossref_primary_10_3389_fonc_2023_1244035
crossref_primary_10_3390_ijms252010982
crossref_primary_10_1016_j_bioorg_2023_106477
crossref_primary_10_3390_ijms25115593
crossref_primary_10_1002_mog2_50
crossref_primary_10_1007_s00253_024_13302_3
crossref_primary_10_1158_0008_5472_CAN_22_1270
crossref_primary_10_1073_pnas_2213363120
crossref_primary_10_3390_jpm14070704
crossref_primary_10_1039_D4MD00175C
crossref_primary_10_3389_fnmol_2024_1398026
crossref_primary_10_1016_j_bioorg_2022_106181
crossref_primary_10_1002_pro_4917
crossref_primary_10_1021_acs_jmedchem_4c02024
crossref_primary_10_1016_j_ejmech_2023_115594
crossref_primary_10_1002_ardp_202300149
crossref_primary_10_3389_fcell_2024_1368171
crossref_primary_10_3390_cancers14235926
crossref_primary_10_1186_s12929_022_00893_0
crossref_primary_10_1039_D5CP00002E
crossref_primary_10_3390_toxins15100588
crossref_primary_10_3390_molecules29010238
crossref_primary_10_2147_DDDT_S460575
crossref_primary_10_1158_2159_8290_CD_24_0174
crossref_primary_10_1016_j_biopha_2023_115212
crossref_primary_10_1038_s41598_024_79136_1
crossref_primary_10_3390_molecules27238438
crossref_primary_10_1016_j_bmc_2024_117680
crossref_primary_10_3389_fphar_2022_863677
crossref_primary_10_1016_j_bbrc_2023_09_023
crossref_primary_10_3390_jcm13082423
crossref_primary_10_1039_D3DT01876H
crossref_primary_10_1002_cbdv_202201030
crossref_primary_10_1021_acs_jmedchem_3c01160
crossref_primary_10_1016_j_acthis_2024_152144
crossref_primary_10_1080_13543776_2024_2363890
crossref_primary_10_3389_fonc_2024_1327933
crossref_primary_10_1007_s12032_024_02303_x
crossref_primary_10_1080_14756366_2023_2241118
crossref_primary_10_1016_j_bmc_2025_118143
crossref_primary_10_3390_ijms231710014
crossref_primary_10_1007_s00296_021_04951_y
crossref_primary_10_3390_ijms25169054
crossref_primary_10_1002_btm2_10710
crossref_primary_10_3389_fcimb_2024_1308362
crossref_primary_10_3390_cancers15204985
crossref_primary_10_1186_s12967_024_05563_3
crossref_primary_10_3389_fnins_2022_836476
crossref_primary_10_1186_s40779_023_00496_2
crossref_primary_10_1016_j_bioorg_2024_107883
crossref_primary_10_1002_cbic_202500096
crossref_primary_10_1007_s00535_022_01915_2
crossref_primary_10_1016_j_bmc_2024_117587
crossref_primary_10_2174_1568026622666220303113445
crossref_primary_10_3389_fmolb_2022_986405
crossref_primary_10_1038_s12276_022_00864_3
crossref_primary_10_1158_1078_0432_CCR_23_1795
crossref_primary_10_1182_bloodadvances_2023010330
crossref_primary_10_3390_cancers16213565
crossref_primary_10_1186_s12964_023_01298_8
crossref_primary_10_3390_ijms23158645
crossref_primary_10_31083_j_ceog4910227
crossref_primary_10_1016_j_jbc_2022_102800
crossref_primary_10_30773_pi_2022_0113
crossref_primary_10_1016_j_metabol_2021_154920
crossref_primary_10_1002_cmdc_202300023
crossref_primary_10_3390_ph17040425
crossref_primary_10_1016_j_bioorg_2025_108348
crossref_primary_10_1021_acs_jmedchem_3c01269
crossref_primary_10_1007_s12035_025_04866_w
crossref_primary_10_1016_j_mam_2023_101194
crossref_primary_10_1016_j_hsr_2023_100137
crossref_primary_10_31083_j_fbl2908287
crossref_primary_10_3390_ijms25042181
crossref_primary_10_1158_1078_0432_CCR_22_3897
crossref_primary_10_1016_j_drudis_2024_104052
crossref_primary_10_1113_JP286505
crossref_primary_10_1080_07391102_2024_2335293
crossref_primary_10_3390_ijms24065964
crossref_primary_10_1089_jop_2023_0163
crossref_primary_10_1016_j_phrs_2024_107431
crossref_primary_10_1152_physiolgenomics_00102_2021
crossref_primary_10_1038_s41417_022_00578_8
crossref_primary_10_1093_nargab_lqae157
crossref_primary_10_3390_ph15040438
crossref_primary_10_3892_br_2024_1884
crossref_primary_10_1021_acs_jmedchem_4c00706
crossref_primary_10_3390_ijms231810211
crossref_primary_10_1111_aji_70007
crossref_primary_10_3390_cancers15143650
crossref_primary_10_3390_ijms222111810
crossref_primary_10_1016_j_semcancer_2023_10_005
crossref_primary_10_3390_molecules28041973
crossref_primary_10_3390_ijms242115913
crossref_primary_10_1016_j_intimp_2024_112246
crossref_primary_10_3103_S0095452724050116
crossref_primary_10_1126_sciadv_adp3687
crossref_primary_10_1172_JCI183391
crossref_primary_10_3390_cancers14215472
crossref_primary_10_1007_s11060_023_04445_w
crossref_primary_10_1111_cbdd_14366
crossref_primary_10_1007_s00277_024_05691_2
crossref_primary_10_1016_j_snb_2022_131882
crossref_primary_10_1016_j_pharmthera_2024_108732
crossref_primary_10_1016_j_heliyon_2024_e33997
crossref_primary_10_1080_15592294_2024_2400423
crossref_primary_10_3390_molecules27123960
crossref_primary_10_1002_1878_0261_13266
crossref_primary_10_3390_pathogens12060810
crossref_primary_10_1080_07391102_2022_2142668
crossref_primary_10_1186_s13148_023_01562_1
crossref_primary_10_1016_j_bcp_2024_116257
crossref_primary_10_1038_s41467_024_49784_y
crossref_primary_10_1016_j_bbi_2022_02_025
crossref_primary_10_3390_ijms25115885
crossref_primary_10_1021_acsmedchemlett_4c00293
crossref_primary_10_3390_genes14020347
crossref_primary_10_2174_0113892029265046231011100327
crossref_primary_10_3389_fmolb_2022_981963
crossref_primary_10_1016_j_tips_2021_07_002
crossref_primary_10_3390_medicina60060888
crossref_primary_10_1016_j_neubiorev_2021_10_042
crossref_primary_10_1016_j_lfs_2022_121211
crossref_primary_10_1101_gad_351444_123
crossref_primary_10_1248_cpb_c23_00027
crossref_primary_10_1631_jzus_B2100780
crossref_primary_10_3390_life14121555
crossref_primary_10_1124_pharmrev_123_000835
crossref_primary_10_1248_cpb_c23_00026
crossref_primary_10_3390_ph17081072
crossref_primary_10_1182_bloodadvances_2022007998
crossref_primary_10_3390_cells13040319
crossref_primary_10_3390_ph15101260
crossref_primary_10_1080_17446651_2023_2183840
crossref_primary_10_1007_s11064_023_03913_z
crossref_primary_10_1016_j_ejmech_2025_117463
crossref_primary_10_1186_s12864_024_10029_3
crossref_primary_10_3390_vaccines12060626
crossref_primary_10_1016_j_mehy_2021_110724
crossref_primary_10_1002_ardp_202300410
crossref_primary_10_1038_s41467_024_48724_0
crossref_primary_10_37349_etat_2023_00166
crossref_primary_10_1007_s12032_023_02049_y
crossref_primary_10_1002_tcr_202300347
crossref_primary_10_1111_cas_16032
crossref_primary_10_1016_j_arr_2023_102003
crossref_primary_10_1016_j_molstruc_2024_139238
crossref_primary_10_3390_ph16020227
crossref_primary_10_3390_ph18020207
crossref_primary_10_1016_j_bbagrm_2024_195007
crossref_primary_10_1016_j_exppara_2024_108716
crossref_primary_10_3748_wjg_v28_i18_1934
crossref_primary_10_14283_jpad_2023_111
crossref_primary_10_1080_07391102_2024_2325104
crossref_primary_10_1186_s40001_024_02108_8
crossref_primary_10_3390_ijms242317072
crossref_primary_10_1007_s13205_023_03912_5
crossref_primary_10_3389_fnins_2023_1259405
crossref_primary_10_2174_0113895575303614240527093106
crossref_primary_10_4110_in_2023_23_e5
crossref_primary_10_1016_j_ccr_2022_214899
crossref_primary_10_1007_s00210_023_02674_4
crossref_primary_10_1016_j_lfs_2022_120946
crossref_primary_10_1016_j_brainres_2024_149121
crossref_primary_10_1039_D2NJ04894A
crossref_primary_10_1080_19768354_2025_2477024
crossref_primary_10_1186_s12964_023_01253_7
crossref_primary_10_1080_14737140_2025_2458156
crossref_primary_10_1242_dmm_050056
crossref_primary_10_1021_acs_jmedchem_3c00226
crossref_primary_10_1007_s00018_024_05406_w
crossref_primary_10_1080_09603123_2024_2399210
crossref_primary_10_1007_s13353_023_00824_1
crossref_primary_10_1016_j_bbcan_2023_188999
crossref_primary_10_1007_s11010_023_04857_2
crossref_primary_10_1016_j_biopha_2024_116374
crossref_primary_10_3390_biom13091301
crossref_primary_10_3390_ph17050620
crossref_primary_10_1073_pnas_2321502121
crossref_primary_10_3892_or_2023_8687
crossref_primary_10_1007_s00726_023_03297_y
crossref_primary_10_1002_psc_3603
crossref_primary_10_3390_ijms23062996
crossref_primary_10_1016_j_arr_2024_102324
crossref_primary_10_1007_s12312_024_01412_y
crossref_primary_10_3389_fcimb_2022_1002817
crossref_primary_10_1016_j_pharmthera_2022_108301
crossref_primary_10_1038_s41598_024_59110_7
crossref_primary_10_3390_separations10060333
crossref_primary_10_1186_s12885_023_11645_0
crossref_primary_10_1080_15548627_2024_2439649
crossref_primary_10_1080_17501911_2024_2430169
crossref_primary_10_1186_s13148_023_01604_8
crossref_primary_10_3389_fimmu_2023_1164514
crossref_primary_10_1002_cmdc_202400194
crossref_primary_10_1016_j_bioorg_2024_108116
crossref_primary_10_1111_febs_16437
crossref_primary_10_3390_ijms23063021
crossref_primary_10_1002_cncr_34974
crossref_primary_10_1016_j_ejmech_2024_116696
crossref_primary_10_1080_17568919_2025_2459589
crossref_primary_10_1002_cmdc_202300655
crossref_primary_10_1021_acschemneuro_4c00346
crossref_primary_10_1002_smll_202300244
crossref_primary_10_1016_j_molmed_2021_07_012
crossref_primary_10_3390_ijms25158429
crossref_primary_10_3390_ijms24054306
crossref_primary_10_1016_j_celrep_2024_114911
crossref_primary_10_1016_j_tins_2022_06_001
crossref_primary_10_1007_s00044_024_03210_6
crossref_primary_10_1016_j_semcdb_2022_09_009
crossref_primary_10_1016_j_rechem_2023_101253
crossref_primary_10_1038_s41598_023_36555_w
crossref_primary_10_1016_j_phymed_2023_154670
crossref_primary_10_1002_btm2_10541
crossref_primary_10_3390_biology12081049
crossref_primary_10_1186_s13072_024_00564_4
crossref_primary_10_1016_j_canlet_2023_216121
crossref_primary_10_1016_j_jneumeth_2025_110365
crossref_primary_10_1007_s11033_024_09353_4
crossref_primary_10_1186_s44356_024_00011_2
crossref_primary_10_1016_j_ejmech_2024_116324
crossref_primary_10_1007_s11060_023_04526_w
Cites_doi 10.1038/s41576-018-0074-2
10.1016/0092-8674(78)90305-7
10.1182/blood-2012-10-461988
10.1146/annurev.pharmtox.45.120403.095825
10.1073/pnas.172511699
10.1158/1078-0432.CCR-10-0925
10.7164/antibiotics.43.1524
10.1038/s41467-020-17099-3
10.3816/CLM.2009.n.082
10.1016/j.ebiom.2019.07.053
10.1093/bioinformatics/17.8.754
10.1073/pnas.1805436115
10.1634/theoncologist.2017-0644
10.1038/43710
10.1016/j.neurobiolaging.2016.03.001
10.1182/blood-2006-06-025999
10.1200/JCO.2010.28.9066
10.1097/COH.0b013e328341242d
10.1016/j.nbd.2011.02.016
10.1080/10428194.2018.1515937
10.1182/blood-2010-10-312603
10.1073/pnas.191375098
10.1002/ana.24260
10.1016/j.ctrv.2018.09.001
10.1158/1078-0432.CCR-16-2526
10.1016/S2352-3018(14)70014-1
10.1038/nchembio.313
10.1016/S1470-2045(16)30375-8
10.1007/s00125-016-4113-2
10.3324/haematol.2018.187617
10.1111/bph.14752
10.1158/1078-0432.CCR-08-1215
10.1182/blood-2016-01-643569
10.1111/febs.15468
10.2217/epi.15.16
10.1073/pnas.51.5.786
10.3109/10428194.2015.1137292
10.1038/sj.onc.1210599
10.1074/jbc.M109861200
10.1042/bj20021321
10.1038/s41580-018-0076-0
10.1016/B978-0-12-394387-3.00002-1
10.1074/jbc.M104935200
10.1186/s13045-016-0266-1
10.1021/acschembio.7b00942
10.1016/j.jmb.2004.02.006
10.1002/ijc.2910490113
10.1038/nature07925
10.1016/S0021-9258(17)44885-X
10.2340/00015555-1886
10.1093/bioinformatics/btu033
10.1056/NEJMoa1916945
10.1073/pnas.0706487104
10.1021/acs.chemrev.7b00181
10.1007/s00280-011-1693-x
10.3109/10428194.2012.656625
10.1038/ncomms15368
10.1016/j.bbagrm.2017.12.002
10.1002/hon.2691
10.1172/JCI92684
10.1080/17460441.2017.1295954
10.1146/annurev-pharmtox-011613-135943
10.1021/acs.biochem.8b00079
10.1074/jbc.M110.146860
10.1038/s41580-018-0081-3
10.1056/NEJMoa041892
10.1016/j.ejmech.2016.05.047
10.1021/acs.jmedchem.0c00830
10.1182/blood-2013-12-516245
10.1215/S1152851704000183
10.1124/jpet.117.244939
10.1093/nar/gkx1037
10.1007/s00277-013-1910-2
10.1016/j.chembiol.2018.04.007
10.2337/db11-0440
10.3109/10428194.2012.664844
10.1007/s13277-015-3781-8
10.1101/cshperspect.a018713
10.1111/j.1474-9726.2011.00680.x
10.1186/s13045-017-0439-6
10.1093/annonc/mdv237
10.1038/nbt.1678
10.1038/nrd4360
10.1159/000498905
10.1093/nar/gkw107
10.1016/j.ccr.2010.10.022
10.1111/bjh.13222
10.1182/blood-2018-11-881268
10.1387/ijdb.082649rb
10.1016/S2352-3026(16)30165-X
10.1038/nrd3478
10.1200/JCO.2014.59.2782
10.1016/S2352-3026(15)00023-X
10.1097/FPC.0b013e32834a8639
10.1016/j.nmd.2016.07.002
10.1111/cen.13154
10.1371/journal.ppat.1005142
10.1074/jbc.M114.596247
10.1080/10428194.2016.1247956
10.1016/j.tips.2015.04.013
10.1038/nn.2333
10.1016/bs.acr.2018.02.006
10.2183/pjab.93.019
10.1093/nar/25.18.3693
10.1093/nar/gky1033
10.1200/JCO.2019.37.15_suppl.7551
10.1021/acschembio.6b00396
10.1016/S1470-2045(14)70440-1
10.1200/JCO.2006.10.2434
10.1002/ana.24249
10.1016/S0092-8674(02)00861-9
10.1016/S2352-3026(18)30174-1
10.1182/bloodadvances.2018019240
10.1172/jci.insight.97903
10.1182/blood.2019001285
10.1016/j.lungcan.2004.03.002
10.1073/pnas.96.9.4868
10.1111/dom.12470
10.1038/s41408-018-0154-8
10.5582/irdr.2016.01024
10.1182/blood-2011-06-362434
10.1038/nbt.1685
10.2217/epi-2016-0160
10.1038/nrg2485
10.1074/jbc.M114.605428
10.1080/13543784.2017.1291630
10.1200/jco.2004.22.90140.7279
10.1080/10428194.2017.1372575
10.1016/j.cell.2011.03.043
10.1016/S2352-3018(16)30055-8
10.1182/blood-2015-09-665018
10.1158/1078-0432.CCR-17-1178
10.1007/s40264-018-0773-9
10.1172/JCI133753
10.1186/s13045-018-0654-9
10.1016/S0002-9440(10)63320-2
10.3390/ijms20071605
10.1074/jbc.M108931200
10.1002/ajh.25577
10.1021/acs.jmedchem.8b01597
10.1080/09546634.2017.1412064
10.1042/BST20130010
10.1021/jm0303094
10.1038/s41588-019-0514-8
10.1182/blood-2012-07-441949
10.1016/S1074-7613(03)00109-2
10.1182/blood-2017-09-806737
10.1016/j.tips.2018.03.003
10.1200/JCO.2008.21.6150
10.1186/1750-1326-8-7
10.1158/1078-0432.CCR-19-2152
10.1002/jcph.625
10.1182/blood-2012-08-450916
10.1002/art.30238
10.3390/cells4020135
10.1016/S0092-8674(03)00939-5
10.1074/jbc.M807045200
10.1016/S1470-2045(19)30164-0
10.1016/S1470-2045(19)30279-7
10.1074/jbc.M111871200
10.1186/s40673-017-0062-x
10.1186/s12885-016-2957-y
10.14348/molcells.2017.0116
10.1001/jamaoncol.2016.0004
10.3109/10428194.2012.661175
10.1101/gad.1809209
10.1200/JCO.2011.37.4223
10.1038/nrdp.2017.46
ContentType Journal Article
Copyright 2021 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Copyright_xml – notice: 2021 The Authors. published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
– notice: 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ACNBI
ADTPV
AOWAS
D8T
DF2
ZZAVC
DOI 10.1111/bcp.14889
DatabaseName Wiley Online Library Open Access (WRLC)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
SWEPUB Uppsala universitet full text
SwePub
SwePub Articles
SWEPUB Freely available online
SWEPUB Uppsala universitet
SwePub Articles full text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access (WRLC)
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1365-2125
EndPage 4597
ExternalDocumentID oai_DiVA_org_uu_469673
33971031
10_1111_bcp_14889
BCP14889
Genre reviewArticle
Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: Swedish Brain Foundation
– fundername: Swedish Research Council
– fundername: Novo Nordisk Foundation
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FIJ
FUBAC
G-S
G.N
GODZA
GX1
H.X
HF~
HGLYW
HYE
HZI
HZ~
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RPM
RX1
SUPJJ
TEORI
TR2
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
ACNBI
ADTPV
AOWAS
D8T
DF2
ZZAVC
ID FETCH-LOGICAL-c4639-92f9c48a3f3f37ba7bc7526bbbb99fc5ab46b84f15c674342fedb2aa80159acd3
IEDL.DBID DR2
ISSN 0306-5251
1365-2125
IngestDate Thu Aug 21 06:50:31 EDT 2025
Thu Jul 10 23:31:22 EDT 2025
Thu Apr 03 06:59:45 EDT 2025
Tue Jul 01 01:59:26 EDT 2025
Thu Apr 24 23:13:00 EDT 2025
Wed Jan 22 16:26:28 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords HDAC inhibition
belinostat
vorinostat
romidepsin
panobinostat
epigenetics
Language English
License Attribution-NonCommercial
http://creativecommons.org/licenses/by-nc/4.0
2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4639-92f9c48a3f3f37ba7bc7526bbbb99fc5ab46b84f15c674342fedb2aa80159acd3
Notes Funding information
Novo Nordisk Foundation; Swedish Brain Foundation; Swedish Research Council
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0001-7112-0921
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.14889
PMID 33971031
PQID 2525663535
PQPubID 23479
PageCount 21
ParticipantIDs swepub_primary_oai_DiVA_org_uu_469673
proquest_miscellaneous_2525663535
pubmed_primary_33971031
crossref_primary_10_1111_bcp_14889
crossref_citationtrail_10_1111_bcp_14889
wiley_primary_10_1111_bcp_14889_BCP14889
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate December 2021
PublicationDateYYYYMMDD 2021-12-01
PublicationDate_xml – month: 12
  year: 2021
  text: December 2021
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle British journal of clinical pharmacology
PublicationTitleAlternate Br J Clin Pharmacol
PublicationYear 2021
References 2007; 104
2004; 22
2004; 165
2017; 86
2019; 94
2011; 117
2021; 288
2010; 18
2011; 60
2002; 99
2002; 277
2020; 11
2013; 121
2013; 8
2007; 109
2016; 37
2018; 46
2009; 12
2018; 39
1990; 43
2018; 2
2009; 10
2018; 5
2018; 1861
2019; 20
2010; 28
2003; 46
2014; 15
2016; 42
2011; 63
2014; 13
2011; 68
2004; 338
2014; 93
2010; 6
2009; 15
2014; 123
2016; 44
2018; 29
2019; 9
2019; 4
2017; 60
2005; 352
2020; 383
2015; 127
1997; 25
2019; 37
2004; 45
2018; 103
2002; 8
2009; 459
2018; 23
2016; 17
2011; 6
2016; 16
2018; 25
2012; 30
2016; 11
2001; 276
2016; 5
2016; 2
2016; 3
2019; 42
2017; 58
2018; 118
2019; 46
2018; 115
2019; 47
2020; 26
2005; 7
2014; 30
2018; 11
2012; 116
2016; 26
2011; 145
2016; 9
2012; 119
2018; 13
2019; 176
2017; 40
2018; 364
2015; 36
2017; 8
2019; 51
2017; 3
2017; 4
2020; 63
2002; 110
2015; 33
2011; 10
2003; 18
2011; 17
2003; 115
1999; 401
1990; 265
2017; 9
2012; 53
2018; 131
2014; 1
2019; 60
1991; 49
2015; 290
2019; 62
2009; 53
2018; 138
2020; 130
2018; 70
2011; 21
1999; 96
2001; 17
2014; 6
2007; 25
2017; 127
2007; 26
2014; 54
2011; 286
2001; 98
2009; 23
2015; 2
2015; 17
2015; 4
2017; 26
2015; 95
2015; 168
2015; 11
2013; 41
2017; 23
2009
2003; 370
2008
2016; 121
2016; 127
1978; 14
2019; 141
2015; 7
2009; 27
2005; 45
2008; 283
2016; 57
2016; 56
2015; 26
2017; 93
2017; 10
2017; 12
2011; 42
2019
2018
2009; 9
2019; 133
1964; 51
2019; 134
2018; 59
2014; 76
2018; 57
e_1_2_14_114_1
e_1_2_14_137_1
e_1_2_14_73_1
e_1_2_14_96_1
e_1_2_14_110_1
e_1_2_14_31_1
e_1_2_14_50_1
e_1_2_14_92_1
e_1_2_14_35_1
e_1_2_14_12_1
e_1_2_14_54_1
Byun SK (e_1_2_14_55_1) 2017; 40
e_1_2_14_39_1
e_1_2_14_16_1
e_1_2_14_58_1
e_1_2_14_182_1
e_1_2_14_6_1
e_1_2_14_140_1
e_1_2_14_121_1
e_1_2_14_163_1
e_1_2_14_107_1
e_1_2_14_144_1
e_1_2_14_125_1
e_1_2_14_167_1
e_1_2_14_103_1
e_1_2_14_148_1
e_1_2_14_85_1
e_1_2_14_129_1
e_1_2_14_2_1
e_1_2_14_20_1
e_1_2_14_62_1
e_1_2_14_81_1
e_1_2_14_24_1
e_1_2_14_43_1
e_1_2_14_66_1
e_1_2_14_28_1
e_1_2_14_89_1
e_1_2_14_47_1
e_1_2_14_170_1
e_1_2_14_151_1
e_1_2_14_119_1
e_1_2_14_132_1
e_1_2_14_174_1
e_1_2_14_155_1
e_1_2_14_115_1
e_1_2_14_136_1
e_1_2_14_178_1
e_1_2_14_72_1
e_1_2_14_95_1
e_1_2_14_159_1
e_1_2_14_111_1
e_1_2_14_30_1
e_1_2_14_53_1
e_1_2_14_91_1
e_1_2_14_11_1
e_1_2_14_34_1
e_1_2_14_57_1
e_1_2_14_15_1
e_1_2_14_38_1
e_1_2_14_76_1
e_1_2_14_99_1
e_1_2_14_181_1
e_1_2_14_120_1
e_1_2_14_143_1
e_1_2_14_162_1
e_1_2_14_185_1
e_1_2_14_7_1
e_1_2_14_108_1
e_1_2_14_124_1
e_1_2_14_147_1
e_1_2_14_166_1
e_1_2_14_104_1
e_1_2_14_84_1
e_1_2_14_128_1
e_1_2_14_100_1
e_1_2_14_42_1
e_1_2_14_80_1
e_1_2_14_3_1
e_1_2_14_61_1
e_1_2_14_23_1
e_1_2_14_46_1
e_1_2_14_65_1
e_1_2_14_27_1
e_1_2_14_88_1
e_1_2_14_69_1
e_1_2_14_150_1
e_1_2_14_131_1
e_1_2_14_154_1
e_1_2_14_173_1
e_1_2_14_116_1
e_1_2_14_135_1
e_1_2_14_158_1
e_1_2_14_177_1
e_1_2_14_94_1
e_1_2_14_112_1
e_1_2_14_75_1
e_1_2_14_52_1
e_1_2_14_90_1
e_1_2_14_71_1
e_1_2_14_10_1
e_1_2_14_56_1
e_1_2_14_33_1
e_1_2_14_14_1
e_1_2_14_98_1
e_1_2_14_37_1
e_1_2_14_79_1
e_1_2_14_161_1
e_1_2_14_180_1
e_1_2_14_165_1
e_1_2_14_8_1
e_1_2_14_109_1
e_1_2_14_142_1
e_1_2_14_184_1
e_1_2_14_123_1
e_1_2_14_169_1
e_1_2_14_105_1
e_1_2_14_146_1
e_1_2_14_60_1
e_1_2_14_83_1
e_1_2_14_127_1
e_1_2_14_101_1
e_1_2_14_41_1
e_1_2_14_64_1
e_1_2_14_4_1
e_1_2_14_45_1
e_1_2_14_68_1
e_1_2_14_22_1
e_1_2_14_87_1
e_1_2_14_49_1
e_1_2_14_26_1
e_1_2_14_19_1
e_1_2_14_172_1
e_1_2_14_130_1
e_1_2_14_176_1
e_1_2_14_153_1
e_1_2_14_117_1
e_1_2_14_134_1
e_1_2_14_157_1
Patnaik A (e_1_2_14_175_1) 2002; 8
e_1_2_14_113_1
e_1_2_14_138_1
e_1_2_14_74_1
e_1_2_14_97_1
e_1_2_14_51_1
e_1_2_14_70_1
e_1_2_14_93_1
e_1_2_14_13_1
e_1_2_14_32_1
e_1_2_14_17_1
e_1_2_14_36_1
e_1_2_14_59_1
e_1_2_14_78_1
e_1_2_14_29_1
e_1_2_14_160_1
e_1_2_14_183_1
e_1_2_14_141_1
e_1_2_14_164_1
e_1_2_14_5_1
Subramanian K (e_1_2_14_139_1) 2019
e_1_2_14_122_1
e_1_2_14_145_1
e_1_2_14_168_1
e_1_2_14_9_1
e_1_2_14_106_1
Rozewicki J (e_1_2_14_77_1) 2019; 47
e_1_2_14_126_1
e_1_2_14_149_1
e_1_2_14_102_1
e_1_2_14_86_1
e_1_2_14_63_1
e_1_2_14_40_1
e_1_2_14_82_1
e_1_2_14_67_1
e_1_2_14_21_1
e_1_2_14_44_1
e_1_2_14_25_1
e_1_2_14_48_1
e_1_2_14_18_1
e_1_2_14_171_1
e_1_2_14_152_1
e_1_2_14_118_1
e_1_2_14_133_1
e_1_2_14_156_1
e_1_2_14_179_1
References_xml – volume: 9
  start-page: 711
  issue: 5
  year: 2017
  end-page: 720
  article-title: Phenylbutyrate and β‐cell function: contribution of histone deacetylases and ER stress inhibition
  publication-title: Epigenomics
– volume: 8
  start-page: 2142
  issue: 7
  year: 2002
  end-page: 2148
  article-title: A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies
  publication-title: Clin Cancer Res
– volume: 277
  start-page: 25748
  issue: 28
  year: 2002
  end-page: 25755
  article-title: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family
  publication-title: J Biol Chem
– volume: 60
  start-page: 116
  issue: 1
  year: 2017
  end-page: 125
  article-title: HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells
  publication-title: Diabetologia
– volume: 59
  start-page: 1271
  issue: 5
  year: 2018
  end-page: 1273
  article-title: Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma
  publication-title: Leuk Lymphoma
– volume: 134
  start-page: 1395
  issue: 17
  year: 2019
  end-page: 1405
  article-title: Oral 5‐azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
  publication-title: Blood
– volume: 25
  start-page: 3693
  issue: 18
  year: 1997
  end-page: 3697
  article-title: Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily
  publication-title: Nucleic Acids Res
– volume: 115
  start-page: E11148
  issue: 47
  year: 2018
  end-page: E11157
  article-title: Inhibition of HDAC3 reverses Alzheimer's disease‐related pathologies in vitro and in the 3xTg‐AD mouse model
  publication-title: Proc Natl Acad Sci U S A
– volume: 26
  start-page: 1000
  issue: 5
  year: 2020
  end-page: 1008
  article-title: Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed or refractory T‐cell lymphoma: results of a phase I dose‐escalation study
  publication-title: Clin Cancer Res
– volume: 364
  start-page: 97
  year: 2018
  end-page: 109
  article-title: Epigenetic histone deacetylation inhibition prevents the development and persistence of temporal lobe epilepsy
  publication-title: J Pharmacol Exp Ther
– volume: 118
  start-page: 1216
  issue: 3
  year: 2018
  end-page: 1252
  article-title: Lysine acetylation goes global: from epigenetics to metabolism and therapeutics
  publication-title: Chem Rev
– volume: 95
  start-page: 72
  issue: 1
  year: 2015
  end-page: 77
  article-title: Vorinostat for refractory or relapsing epidermotropic T‐cell lymphoma: a retrospective cohort study of 15 patients
  publication-title: Acta Derm Venereol
– volume: 115
  start-page: 727
  issue: 6
  year: 2003
  end-page: 738
  article-title: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
  publication-title: Cell
– volume: 459
  start-page: 55
  issue: 7243
  year: 2009
  end-page: 60
  article-title: HDAC2 negatively regulates memory formation and synaptic plasticity
  publication-title: Nature
– volume: 23
  start-page: 3307
  issue: 13
  year: 2017
  end-page: 3315
  article-title: Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma
  publication-title: Clin Cancer Res
– volume: 2
  start-page: e160
  issue: 4
  year: 2015
  end-page: e165
  article-title: Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T‐cell lymphoma: a non‐randomised, phase 1b/2 study
  publication-title: The Lancet Haematology
– volume: 338
  start-page: 17
  issue: 1
  year: 2004
  end-page: 31
  article-title: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis
  publication-title: J Mol Biol
– volume: 20
  start-page: 102
  issue: 2
  year: 2019
  end-page: 115
  article-title: Integrative regulation of physiology by histone deacetylase 3
  publication-title: Nat Rev Mol Cell Biol
– volume: 28
  start-page: 4485
  issue: 29
  year: 2010
  end-page: 4491
  article-title: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T‐cell lymphoma
  publication-title: J Clin Oncol
– volume: 39
  start-page: 525
  issue: 6
  year: 2018
  end-page: 535
  article-title: Orphan drugs and their impact on pharmaceutical development
  publication-title: Trends Pharmacol Sci
– volume: 277
  start-page: 187
  issue: 1
  year: 2002
  end-page: 193
  article-title: Isolation and characterization of mammalian HDAC10, a novel histone deacetylase
  publication-title: J Biol Chem
– volume: 43
  start-page: 1524
  issue: 12
  year: 1990
  end-page: 1532
  article-title: Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents
  publication-title: J Antibiot (Tokyo)
– volume: 123
  start-page: 2636
  issue: 17
  year: 2014
  end-page: 2644
  article-title: How I treat the peripheral T‐cell lymphomas
  publication-title: Blood
– volume: 60
  start-page: 912
  issue: 4
  year: 2019
  end-page: 919
  article-title: A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T‐cell and diffuse large B‐cell lymphoma; the Canadian cancer trials group LY.15 study
  publication-title: Leuk Lymphoma
– volume: 121
  start-page: 451
  year: 2016
  end-page: 483
  article-title: Inside HDACs with more selective HDAC inhibitors
  publication-title: Eur J Med Chem
– volume: 26
  start-page: 5310
  issue: 37
  year: 2007
  end-page: 5318
  article-title: HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention
  publication-title: Oncogene
– volume: 96
  start-page: 4868
  issue: 9
  year: 1999
  end-page: 4873
  article-title: Three proteins define a class of human histone deacetylases related to yeast Hda1p
  publication-title: Proc Natl Acad Sci USA
– volume: 10
  start-page: 69
  issue: 1
  year: 2017
  article-title: Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real‐world study in China
  publication-title: J Hematol Oncol
– volume: 17
  start-page: 754
  issue: 8
  year: 2001
  end-page: 755
  article-title: MRBAYES: Bayesian inference of phylogenetic trees
  publication-title: Bioinformatics
– volume: 176
  start-page: S297
  issue: S1
  year: 2019
  end-page: S396
  article-title: The Concise Guide to Pharmacology 2019/20: Enzymes
  publication-title: Br J Pharmacol
– volume: 4
  issue: 5
  year: 2019
  article-title: PTHrP targets HDAC4 and HDAC5 to repress chondrocyte hypertrophy
  publication-title: JCI Insight
– volume: 37
  start-page: 931
  issue: 1
  year: 2016
  end-page: 942
  article-title: Phenylbutyrate‐a pan‐HDAC inhibitor‐suppresses proliferation of glioblastoma LN‐229 cell line
  publication-title: Tumour Biol
– volume: 1
  start-page: e13
  issue: 1
  year: 2014
  end-page: e21
  article-title: Panobinostat, a histone deacetylase inhibitor, for latent‐virus reactivation in HIV‐infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
  publication-title: Lancet HIV
– volume: 53
  start-page: 1501
  issue: 8
  year: 2012
  end-page: 1508
  article-title: Vorinostat combined with bexarotene for treatment of cutaneous T‐cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
  publication-title: Leuk Lymphoma
– volume: 3
  start-page: e463
  issue: 10
  year: 2016
  end-page: e472
  article-title: Combined effect of Vacc‐4x, recombinant human granulocyte macrophage colony‐stimulating factor vaccination, and romidepsin on the HIV‐1 reservoir (REDUC): a single‐arm, phase 1B/2A trial
  publication-title: Lancet HIV
– year: 2008
– volume: 11
  start-page: 3282
  issue: 1
  year: 2020
  article-title: A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction
  publication-title: Nat Commun
– volume: 401
  start-page: 188
  issue: 6749
  year: 1999
  end-page: 193
  article-title: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
  publication-title: Nature
– volume: 18
  start-page: 687
  issue: 5
  year: 2003
  end-page: 698
  article-title: HDAC7, a thymus‐specific class II histone deacetylase, regulates Nur77 transcription and TCR‐mediated apoptosis
  publication-title: Immunity
– volume: 26
  start-page: 643
  issue: 10
  year: 2016
  end-page: 649
  article-title: Histological effects of givinostat in boys with Duchenne muscular dystrophy
  publication-title: Neuromuscul Disord
– volume: 121
  start-page: 2038
  issue: 11
  year: 2013
  end-page: 2050
  article-title: Dosage‐dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c‐Myc collaborating genes and p53 function
  publication-title: Blood
– volume: 5
  start-page: e628
  issue: 12
  year: 2018
  end-page: e640
  article-title: Bortezomib, lenalidomide, and dexamethasone with panobinostat for front‐line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial
  publication-title: Lancet Haematol
– volume: 11
  issue: 9
  year: 2015
  article-title: The depsipeptide romidepsin reverses HIV‐1 latency in vivo
  publication-title: PLoS Pathog
– year: 2019
– volume: 10
  start-page: 32
  issue: 1
  year: 2009
  end-page: 42
  article-title: The many roles of histone deacetylases in development and physiology: implications for disease and therapy
  publication-title: Nat Rev Genet
– volume: 22
  start-page: 7279
  issue: 14_suppl
  year: 2004
  end-page: 7279
  article-title: Dose escalation study of pivanex (a histone deacetylase inhibitor) in combination with docetaxel for advanced non‐small cell lung cancer
  publication-title: J Clin Oncol
– volume: 116
  start-page: 39
  year: 2012
  end-page: 86
  article-title: Mechanisms of resistance to histone deacetylase inhibitors
  publication-title: Adv Cancer Res
– volume: 63
  start-page: 12460
  issue: 21
  year: 2020
  end-page: 12484
  article-title: Thirty years of HDAC inhibitors: 2020 insight and hindsight
  publication-title: J Med Chem
– volume: 370
  start-page: 737
  issue: Pt 3
  year: 2003
  end-page: 749
  article-title: Histone deacetylases (HDACs): characterization of the classical HDAC family
  publication-title: Biochem J
– volume: 109
  start-page: 31
  issue: 1
  year: 2007
  end-page: 39
  article-title: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T‐cell lymphoma (CTCL)
  publication-title: Blood
– volume: 45
  start-page: 381
  issue: 3
  year: 2004
  end-page: 386
  article-title: Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN‐9) in advanced non‐small cell lung cancer
  publication-title: Lung Cancer
– volume: 28
  start-page: 1069
  issue: 10
  year: 2010
  end-page: 1078
  article-title: Epigenetic modifications as therapeutic targets
  publication-title: Nat Biotechnol
– volume: 3
  start-page: e572
  issue: 12
  year: 2016
  end-page: e580
  article-title: Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK‐six): a multicentre, open‐label, phase 1/2 trial
  publication-title: Lancet Haematol
– volume: 12
  start-page: 345
  issue: 4
  year: 2017
  end-page: 362
  article-title: Exploring the epigenetic drug discovery landscape
  publication-title: Expert Opin Drug Discovery
– volume: 53
  start-page: 1820
  issue: 9
  year: 2012
  end-page: 1823
  article-title: Phase II trial of the pan‐deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
  publication-title: Leuk Lymphoma
– year: 2019
  article-title: Correction of Niemann‐Pick type C1 disease with the histone deacetylase inhibitor valproic acid
  publication-title: bioRxiv
– volume: 6
  start-page: 238
  issue: 3
  year: 2010
  end-page: 243
  article-title: Chemical phylogenetics of histone deacetylases
  publication-title: Nat Chem Biol
– volume: 130
  start-page: 2966
  issue: 6
  year: 2020
  end-page: 2977
  article-title: Salt‐inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling
  publication-title: J Clin Invest
– volume: 288
  start-page: 1201
  issue: 4
  year: 2021
  end-page: 1223
  article-title: Loss of HDAC11 accelerates skeletal muscle regeneration in mice
  publication-title: FEBS J
– volume: 49
  start-page: 66
  issue: 1
  year: 1991
  end-page: 72
  article-title: Derivatives of butyric acid as potential anti‐neoplastic agents
  publication-title: Int J Cancer
– volume: 145
  start-page: 607
  issue: 4
  year: 2011
  end-page: 621
  article-title: Class IIa histone deacetylases are hormone‐activated regulators of FOXO and mammalian glucose homeostasis
  publication-title: Cell
– volume: 27
  start-page: 5410
  issue: 32
  year: 2009
  end-page: 5417
  article-title: Phase II multi‐institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T‐cell lymphoma
  publication-title: J Clin Oncol
– volume: 17
  start-page: 703
  issue: 7
  year: 2015
  end-page: 707
  article-title: Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats
  publication-title: Diabetes Obes Metab
– volume: 127
  start-page: 713
  year: 2015
  end-page: 721
  article-title: Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
  publication-title: Blood
– volume: 13
  start-page: 673
  issue: 9
  year: 2014
  end-page: 691
  article-title: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
  publication-title: Nat Rev Drug Discov
– volume: 9
  start-page: 412
  issue: 6
  year: 2009
  end-page: 416
  article-title: Evaluation of the long‐term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T‐cell lymphoma
  publication-title: Clin Lymphoma Myeloma
– volume: 352
  start-page: 1967
  issue: 19
  year: 2005
  end-page: 1976
  article-title: Decreased histone deacetylase activity in chronic obstructive pulmonary disease
  publication-title: N Engl J Med
– volume: 41
  start-page: 741
  issue: 3
  year: 2013
  end-page: 749
  article-title: The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co‐stars with multiple leading parts
  publication-title: Biochem Soc Trans
– volume: 37
  start-page: 7551
  issue: 15_suppl
  year: 2019
  end-page: 7551
  article-title: A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein‐Barr virus (EBV)‐associated lymphomas
  publication-title: J Clin Oncol
– volume: 20
  start-page: 156
  issue: 3
  year: 2019
  end-page: 174
  article-title: Functions and mechanisms of non‐histone protein acetylation
  publication-title: Nat Rev Mol Cell Biol
– volume: 98
  start-page: 10572
  issue: 19
  year: 2001
  end-page: 10577
  article-title: Cloning and characterization of a histone deacetylase, HDAC9
  publication-title: Proc Natl Acad Sci U S A
– volume: 15
  start-page: 1195
  issue: 11
  year: 2014
  end-page: 1206
  article-title: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double‐blind phase 3 trial
  publication-title: Lancet Oncol
– volume: 6
  issue: 4
  year: 2014
  article-title: Erasers of histone acetylation: the histone deacetylase enzymes
  publication-title: Cold Spring Harb Perspect Biol
– volume: 46
  start-page: 170
  year: 2019
  end-page: 183
  article-title: Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma
  publication-title: EBioMedicine
– volume: 58
  start-page: 1306
  issue: 6
  year: 2017
  end-page: 1319
  article-title: Targeting histone deacetylases in T‐cell lymphoma
  publication-title: Leuk Lymphoma
– volume: 9
  start-page: 38
  issue: 1
  year: 2016
  article-title: A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T‐cell lymphoma patients
  publication-title: J Hematol Oncol
– volume: 121
  start-page: 1335
  issue: 8
  year: 2013
  end-page: 1344
  article-title: Histone deacetylase 1 and 2 are essential for normal T‐cell development and genomic stability in mice
  publication-title: Blood
– volume: 70
  start-page: 199
  year: 2018
  end-page: 208
  article-title: Drug resistance in multiple myeloma
  publication-title: Cancer Treat Rev
– volume: 8
  issue: 1
  year: 2017
  article-title: Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
  publication-title: Nat Commun
– volume: 47
  start-page: D1102
  issue: D1
  year: 2019
  end-page: D1109
  article-title: PubChem 2019 update: improved access to chemical data
  publication-title: Nucleic Acids Res
– volume: 8
  year: 2013
  article-title: HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
  publication-title: Mol Neurodegener
– volume: 57
  start-page: 3105
  issue: 22
  year: 2018
  end-page: 3114
  article-title: Polyamine deacetylase structure and catalysis: prokaryotic acetylpolyamine amidohydrolase and eukaryotic HDAC10
  publication-title: Biochemistry
– volume: 16
  start-page: 918
  issue: 1
  year: 2016
  article-title: Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck‐V‐CHANCE trial
  publication-title: BMC Cancer
– volume: 68
  start-page: 805
  issue: 3
  year: 2011
  end-page: 813
  article-title: Effect of ketoconazole‐mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
  publication-title: Cancer Chemother Pharmacol
– volume: 165
  start-page: 553
  issue: 2
  year: 2004
  end-page: 564
  article-title: Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues
  publication-title: Am J Pathol
– volume: 131
  start-page: 397
  issue: 4
  year: 2018
  end-page: 407
  article-title: A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T‐cell lymphoma
  publication-title: Blood
– volume: 276
  start-page: 35826
  issue: 38
  year: 2001
  end-page: 35835
  article-title: Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo
  publication-title: J Biol Chem
– volume: 42
  start-page: 496
  issue: 3
  year: 2011
  end-page: 505
  article-title: Prolonged treatment with pimelic o‐aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model
  publication-title: Neurobiol Dis
– volume: 13
  start-page: 685
  issue: 3
  year: 2018
  end-page: 693
  article-title: Histone deacetylase 11 is a fatty‐acid deacylase
  publication-title: ACS Chem Biol
– volume: 6
  start-page: 25
  issue: 1
  year: 2011
  end-page: 29
  article-title: Histone deacetylase inhibitors and HIV latency
  publication-title: Curr Opin HIV AIDS
– volume: 56
  start-page: 461
  issue: 4
  year: 2016
  end-page: 473
  article-title: Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48‐hour continuous infusion in patients with cancer
  publication-title: J Clin Pharmacol
– volume: 2
  start-page: 1386
  issue: 12
  year: 2018
  end-page: 1392
  article-title: Valproate in combination with rituximab and CHOP as first‐line therapy in diffuse large B‐cell lymphoma (VALFRID)
  publication-title: Blood Adv
– year: 2009
– volume: 20
  issue: 7
  year: 2019
  article-title: HDAC6 modulates signaling pathways relevant to synaptic biology and neuronal differentiation in human stem‐cell‐derived neurons
  publication-title: Int J Mol Sci
– volume: 18
  start-page: 436
  issue: 5
  year: 2010
  end-page: 447
  article-title: Hdac3 is essential for the maintenance of chromatin structure and genome stability
  publication-title: Cancer Cell
– volume: 76
  start-page: 522
  issue: 4
  year: 2014
  end-page: 528
  article-title: Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length
  publication-title: Ann Neurol
– volume: 11
  start-page: 2685
  issue: 10
  year: 2016
  end-page: 2692
  article-title: HDAC8 catalyzes the hydrolysis of long chain fatty acyl lysine
  publication-title: ACS Chem Biol
– volume: 21
  start-page: 760
  issue: 11
  year: 2011
  end-page: 768
  article-title: Impact of UDP‐gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer
  publication-title: Pharmacogenet Genomics
– volume: 283
  start-page: 35402
  issue: 51
  year: 2008
  end-page: 35409
  article-title: Pimelic diphenylamide 106 is a slow, tight‐binding inhibitor of class I histone deacetylases
  publication-title: J Biol Chem
– volume: 9
  start-page: 1
  year: 2019
  end-page: 9
  article-title: Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
  publication-title: Blood Cancer J
– volume: 36
  start-page: 481
  issue: 7
  year: 2015
  end-page: 492
  article-title: HDAC8: a multifaceted target for therapeutic interventions
  publication-title: Trends Pharmacol Sci
– volume: 44
  start-page: 5095
  issue: 11
  year: 2016
  end-page: 5104
  article-title: Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor
  publication-title: Nucleic Acids Res
– year: 2018
– volume: 46
  start-page: 5097
  issue: 24
  year: 2003
  end-page: 5116
  article-title: Histone deacetylase inhibitors
  publication-title: J Med Chem
– volume: 47
  start-page: W5
  issue: W1
  year: 2019
  end-page: W10
  article-title: MAFFT‐DASH: integrated protein sequence and structural alignment
  publication-title: Nucleic Acids Res
– volume: 42
  start-page: 35
  year: 2016
  end-page: 40
  article-title: Suberoylanilide hydroxamic acid increases progranulin production in iPSC‐derived cortical neurons of frontotemporal dementia patients
  publication-title: Neurobiol Aging
– volume: 286
  start-page: 4819
  issue: 6
  year: 2011
  end-page: 4828
  article-title: Neuroprotection by histone deacetylase‐7 (HDAC7) occurs by inhibition of c‐jun expression through a deacetylase‐independent mechanism
  publication-title: J Biol Chem
– volume: 23
  start-page: 516
  issue: 5
  year: 2018
  end-page: 517
  article-title: Panobinostat and multiple myeloma in 2018
  publication-title: Oncologist
– volume: 26
  start-page: 481
  issue: 4
  year: 2017
  end-page: 487
  article-title: Efficacy of hydralazine and valproate in cutaneous T‐cell lymphoma, a phase II study
  publication-title: Expert Opin Investig Drugs
– volume: 10
  start-page: 579
  issue: 8
  year: 2011
  end-page: 590
  article-title: Trends in the exploitation of novel drug targets
  publication-title: Nat Rev Drug Discov
– volume: 30
  start-page: 1312
  issue: 9
  year: 2014
  end-page: 1313
  article-title: RAxML version 8: a tool for phylogenetic analysis and post‐analysis of large phylogenies
  publication-title: Bioinformatics
– volume: 133
  start-page: 1703
  issue: 16
  year: 2019
  end-page: 1714
  article-title: The 2018 update of the WHO‐EORTC classification for primary cutaneous lymphomas
  publication-title: Blood
– volume: 138
  start-page: 183
  year: 2018
  end-page: 211
  article-title: Advances and challenges of HDAC inhibitors in cancer therapeutics
  publication-title: Adv Cancer Res
– volume: 20
  start-page: 109
  issue: 2
  year: 2019
  end-page: 127
  article-title: Clinical epigenetics: seizing opportunities for translation
  publication-title: Nat Rev Genet
– volume: 11
  start-page: 111
  issue: 1
  year: 2018
  article-title: Histone deacetylase 6 in cancer
  publication-title: J Hematol Oncol
– volume: 10
  start-page: 418
  issue: 3
  year: 2011
  end-page: 428
  article-title: Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice
  publication-title: Aging Cell
– volume: 17
  start-page: 937
  issue: 4
  year: 2011
  end-page: 946
  article-title: Impact of ABCB1 allelic variants on QTc interval prolongation
  publication-title: Clin Cancer Res
– volume: 20
  start-page: 746
  issue: 6
  year: 2019
  end-page: 748
  article-title: Genetics to epigenetics: targeting histone deacetylases in hormone receptor‐positive metastatic breast cancer
  publication-title: Lancet Oncol
– volume: 37
  start-page: 569
  issue: 5
  year: 2019
  end-page: 577
  article-title: Romidepsin treatment for relapsed or refractory peripheral and cutaneous T‐cell lymphoma: real‐life data from a national multicenter observational study
  publication-title: Hematol Oncol
– volume: 4
  start-page: 135
  issue: 2
  year: 2015
  end-page: 168
  article-title: HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities
  publication-title: Cell
– volume: 51
  start-page: 1580
  issue: 11
  year: 2019
  end-page: 1587
  article-title: HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype
  publication-title: Nat Genet
– volume: 42
  start-page: 235
  issue: 2
  year: 2019
  end-page: 245
  article-title: Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
  publication-title: Drug Saf
– volume: 117
  start-page: 5827
  issue: 22
  year: 2011
  end-page: 5834
  article-title: Phase 2 trial of romidepsin in patients with peripheral T‐cell lymphoma
  publication-title: Blood
– volume: 168
  start-page: 811
  issue: 6
  year: 2015
  end-page: 819
  article-title: A Phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma
  publication-title: Br J Haematol
– volume: 20
  start-page: 806
  issue: 6
  year: 2019
  end-page: 815
  article-title: Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor‐positive breast cancer (ACE): a randomised, double‐blind, placebo‐controlled, phase 3 trial
  publication-title: Lancet Oncol
– volume: 63
  start-page: 1452
  issue: 5
  year: 2011
  end-page: 1458
  article-title: Safety and efficacy of an oral histone deacetylase inhibitor in systemic‐onset juvenile idiopathic arthritis
  publication-title: Arthritis Rheum
– volume: 94
  start-page: 1027
  issue: 9
  year: 2019
  end-page: 1041
  article-title: Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management
  publication-title: Am J Hematol
– volume: 57
  start-page: 2370
  issue: 10
  year: 2016
  end-page: 2374
  article-title: Romidepsin in relapsed/refractory T‐cell lymphomas: Italian experience and results of a named patient program
  publication-title: Leuk Lymphoma
– volume: 290
  start-page: 118
  issue: 1
  year: 2015
  end-page: 126
  article-title: Histone deacetylase 7 (Hdac7) suppresses chondrocyte proliferation and β‐catenin activity during endochondral ossification
  publication-title: J Biol Chem
– volume: 26
  start-page: 1766
  issue: 8
  year: 2015
  end-page: 1771
  article-title: Results from a multicenter, open‐label, pivotal phase II study of chidamide in relapsed or refractory peripheral T‐cell lymphoma
  publication-title: Ann Oncol
– volume: 99
  start-page: 13425
  issue: 21
  year: 2002
  end-page: 13430
  article-title: Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes
  publication-title: Proc Natl Acad Sci U S A
– volume: 25
  start-page: 3109
  issue: 21
  year: 2007
  end-page: 3115
  article-title: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T‐cell lymphoma
  publication-title: J Clin Oncol
– volume: 53
  start-page: 275
  issue: 2–3
  year: 2009
  end-page: 289
  article-title: Histone deacetylase HDAC1/HDAC2‐controlled embryonic development and cell differentiation
  publication-title: Int J Dev Biol
– volume: 3
  start-page: 17046
  issue: 1
  year: 2017
  article-title: Multiple myeloma
  publication-title: Nat Rev Dis Primers
– volume: 127
  start-page: 3126
  issue: 8
  year: 2017
  end-page: 3135
  article-title: Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
  publication-title: J Clin Invest
– volume: 7
  start-page: 177
  issue: 2
  year: 2005
  end-page: 182
  article-title: Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study
  publication-title: Neuro Oncol
– volume: 30
  start-page: 631
  issue: 6
  year: 2012
  end-page: 636
  article-title: Results from a pivotal, open‐label, phase II study of romidepsin in relapsed or refractory peripheral T‐cell lymphoma after prior systemic therapy
  publication-title: J Clin Oncol
– volume: 93
  start-page: 297
  issue: 5
  year: 2017
  end-page: 321
  article-title: Chemical and structural biology of protein lysine deacetylases
  publication-title: Proc Jpn Acad Ser B Phys Biol Sci
– volume: 103
  start-page: 416
  year: 2018
  end-page: 418
  article-title: A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T‐cell lymphoma
  publication-title: Haematologica
– volume: 53
  start-page: 1722
  issue: 9
  year: 2012
  end-page: 1727
  article-title: Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
  publication-title: Leuk Lymphoma
– volume: 76
  start-page: 489
  issue: 4
  year: 2014
  end-page: 508
  article-title: Epigenetic therapy for Friedreich ataxia
  publication-title: Ann Neurol
– volume: 60
  start-page: 2861
  issue: 11
  year: 2011
  end-page: 2871
  article-title: Specific control of pancreatic endocrine β‐ and δ‐cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9
  publication-title: Diabetes
– volume: 290
  start-page: 5028
  issue: 8
  year: 2015
  end-page: 5040
  article-title: Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1
  publication-title: J Biol Chem
– volume: 46
  start-page: 1074
  year: 2018
  end-page: 1082
  article-title: DrugBank 5.0: a major update to the DrugBank database for 2018
  publication-title: Nucleic Acids Res
– volume: 119
  start-page: 1008
  issue: 4
  year: 2012
  end-page: 1017
  article-title: Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents
  publication-title: Blood
– volume: 2
  start-page: 790
  issue: 6
  year: 2016
  end-page: 793
  article-title: Durable responses with maintenance dose‐sparing regimens of romidepsin in cutaneous T‐cell lymphoma
  publication-title: JAMA Oncol
– volume: 45
  start-page: 495
  issue: 1
  year: 2005
  end-page: 528
  article-title: Clinical development of histone deacetylase inhibitors as anticancer agents
  publication-title: Annu Rev Pharmacol Toxicol
– volume: 14
  start-page: 105
  issue: 1
  year: 1978
  end-page: 113
  article-title: Sodium butyrate inhibits histone deacetylation in cultured cells
  publication-title: Cell
– volume: 7
  start-page: 641
  issue: 4
  year: 2015
  end-page: 652
  article-title: Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy
  publication-title: Epigenomics
– volume: 86
  start-page: 128
  issue: 1
  year: 2017
  end-page: 133
  article-title: A phase II trial of valproic acid in patients with advanced, radioiodine‐resistant thyroid cancers of follicular cell origin
  publication-title: Clin Endocrinol (Oxf)
– volume: 104
  start-page: 17335
  issue: 44
  year: 2007
  end-page: 17340
  article-title: Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
  publication-title: Proc Natl Acad Sci U S A
– volume: 265
  start-page: 17174
  issue: 28
  year: 1990
  end-page: 17179
  article-title: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
  publication-title: J Biol Chem
– volume: 23
  start-page: 1625
  issue: 14
  year: 2009
  end-page: 1630
  article-title: Epigenetic control of skull morphogenesis by histone deacetylase 8
  publication-title: Genes Dev
– volume: 25
  start-page: 849
  issue: 7
  year: 2018
  end-page: 856.e8
  article-title: Histone deacetylase 11 is an ε‐N‐myristoyllysine hydrolase
  publication-title: Cell Chem Biol
– volume: 93
  start-page: 89
  issue: 1
  year: 2014
  end-page: 98
  article-title: A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
  publication-title: Ann Hematol
– volume: 141
  start-page: 216
  issue: 4
  year: 2019
  end-page: 221
  article-title: Romidepsin‐bendamustine combination for relapsed/refractory T cell lymphoma
  publication-title: Acta Haematol
– volume: 23
  start-page: 7199
  issue: 23
  year: 2017
  end-page: 7208
  article-title: Immunomodulation by entinostat in renal cell carcinoma patients receiving high‐dose interleukin 2: a multicenter, single‐arm, phase I/II trial (NCI‐CTEP#7870)
  publication-title: Clin Cancer Res
– volume: 17
  start-page: 1569
  issue: 11
  year: 2016
  end-page: 1578
  article-title: Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
  publication-title: Lancet Oncol
– volume: 121
  start-page: 3459
  issue: 17
  year: 2013
  end-page: 3468
  article-title: A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
  publication-title: Blood
– volume: 62
  start-page: 3898
  issue: 8
  year: 2019
  end-page: 3923
  article-title: Discovery of novel Janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies
  publication-title: J Med Chem
– volume: 33
  start-page: 2492
  issue: 23
  year: 2015
  end-page: 2499
  article-title: Belinostat in patients with relapsed or refractory peripheral T‐cell lymphoma: results of the pivotal phase II BELIEF (CLN‐19) study
  publication-title: J Clin Oncol
– volume: 5
  start-page: 185
  issue: 3
  year: 2016
  end-page: 191
  article-title: Development of chidamide for peripheral T‐cell lymphoma, the first orphan drug approved in China
  publication-title: Intractable Rare Dis Res
– volume: 383
  start-page: 919
  issue: 10
  year: 2020
  end-page: 930
  article-title: Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis
  publication-title: N Engl J Med
– volume: 40
  start-page: 667
  issue: 9
  year: 2017
  end-page: 676
  article-title: HDAC11 inhibits myoblast differentiation through repression of MyoD‐dependent transcription
  publication-title: Mol Cells
– volume: 15
  start-page: 1496
  issue: 4
  year: 2009
  end-page: 1503
  article-title: Population pharmacokinetics of romidepsin in patients with cutaneous T‐cell lymphoma and relapsed peripheral T‐cell lymphoma
  publication-title: Clin Cancer Res
– volume: 1861
  start-page: 54
  issue: 1
  year: 2018
  end-page: 59
  article-title: HDAC11 is a regulator of diverse immune functions
  publication-title: Biochim Biophys Acta Gene Regul Mech
– volume: 127
  start-page: 2375
  issue: 20
  year: 2016
  end-page: 2390
  article-title: The 2016 revision of the World Health Organization classification of lymphoid neoplasms
  publication-title: Blood
– volume: 28
  start-page: 1057
  issue: 10
  year: 2010
  end-page: 1068
  article-title: Epigenetic modifications and human disease
  publication-title: Nat Biotechnol
– volume: 51
  start-page: 786
  issue: 5
  year: 1964
  end-page: 794
  article-title: Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis
  publication-title: Proc Natl Acad Sci U S A
– volume: 110
  start-page: 479
  issue: 4
  year: 2002
  end-page: 488
  article-title: Class II histone deacetylases act as signal‐responsive repressors of cardiac hypertrophy
  publication-title: Cell
– volume: 4
  start-page: 4
  issue: 1
  year: 2017
  article-title: Friedreich ataxia: current status and future prospects
  publication-title: Cerebellum Ataxias
– volume: 277
  start-page: 3350
  issue: 5
  year: 2002
  end-page: 3356
  article-title: Molecular cloning and characterization of a novel histone deacetylase HDAC10
  publication-title: J Biol Chem
– volume: 54
  start-page: 9
  issue: 1
  year: 2014
  end-page: 26
  article-title: The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication
  publication-title: Annu Rev Pharmacol Toxicol
– volume: 12
  start-page: 829
  issue: 7
  year: 2009
  end-page: 838
  article-title: HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta‐catenin‐TCF interaction
  publication-title: Nat Neurosci
– volume: 29
  start-page: 522
  issue: 5
  year: 2018
  end-page: 530
  article-title: An exploratory cost‐effectiveness analysis of systemic treatments for cutaneous T‐cell lymphoma
  publication-title: J Dermatolog Treat
– ident: e_1_2_14_4_1
  doi: 10.1038/s41576-018-0074-2
– ident: e_1_2_14_76_1
  doi: 10.1016/0092-8674(78)90305-7
– ident: e_1_2_14_59_1
  doi: 10.1182/blood-2012-10-461988
– ident: e_1_2_14_73_1
  doi: 10.1146/annurev.pharmtox.45.120403.095825
– ident: e_1_2_14_19_1
  doi: 10.1073/pnas.172511699
– ident: e_1_2_14_101_1
  doi: 10.1158/1078-0432.CCR-10-0925
– ident: e_1_2_14_71_1
  doi: 10.7164/antibiotics.43.1524
– ident: e_1_2_14_45_1
  doi: 10.1038/s41467-020-17099-3
– ident: e_1_2_14_94_1
  doi: 10.3816/CLM.2009.n.082
– ident: e_1_2_14_180_1
  doi: 10.1016/j.ebiom.2019.07.053
– ident: e_1_2_14_79_1
  doi: 10.1093/bioinformatics/17.8.754
– ident: e_1_2_14_173_1
– ident: e_1_2_14_63_1
  doi: 10.1073/pnas.1805436115
– ident: e_1_2_14_136_1
  doi: 10.1634/theoncologist.2017-0644
– ident: e_1_2_14_74_1
  doi: 10.1038/43710
– ident: e_1_2_14_140_1
  doi: 10.1016/j.neurobiolaging.2016.03.001
– ident: e_1_2_14_93_1
  doi: 10.1182/blood-2006-06-025999
– ident: e_1_2_14_98_1
  doi: 10.1200/JCO.2010.28.9066
– ident: e_1_2_14_64_1
  doi: 10.1097/COH.0b013e328341242d
– ident: e_1_2_14_155_1
  doi: 10.1016/j.nbd.2011.02.016
– ident: e_1_2_14_117_1
  doi: 10.1080/10428194.2018.1515937
– ident: e_1_2_14_111_1
  doi: 10.1182/blood-2010-10-312603
– ident: e_1_2_14_30_1
  doi: 10.1073/pnas.191375098
– ident: e_1_2_14_158_1
  doi: 10.1002/ana.24260
– ident: e_1_2_14_87_1
– ident: e_1_2_14_126_1
  doi: 10.1016/j.ctrv.2018.09.001
– ident: e_1_2_14_147_1
  doi: 10.1158/1078-0432.CCR-16-2526
– ident: e_1_2_14_142_1
  doi: 10.1016/S2352-3018(14)70014-1
– ident: e_1_2_14_38_1
  doi: 10.1038/nchembio.313
– ident: e_1_2_14_146_1
  doi: 10.1016/S1470-2045(16)30375-8
– ident: e_1_2_14_160_1
– ident: e_1_2_14_68_1
  doi: 10.1007/s00125-016-4113-2
– ident: e_1_2_14_115_1
  doi: 10.3324/haematol.2018.187617
– ident: e_1_2_14_185_1
  doi: 10.1111/bph.14752
– ident: e_1_2_14_100_1
  doi: 10.1158/1078-0432.CCR-08-1215
– ident: e_1_2_14_86_1
– ident: e_1_2_14_108_1
  doi: 10.1182/blood-2016-01-643569
– ident: e_1_2_14_54_1
  doi: 10.1111/febs.15468
– ident: e_1_2_14_151_1
  doi: 10.2217/epi.15.16
– ident: e_1_2_14_7_1
  doi: 10.1073/pnas.51.5.786
– ident: e_1_2_14_102_1
  doi: 10.3109/10428194.2015.1137292
– ident: e_1_2_14_6_1
  doi: 10.1038/sj.onc.1210599
– ident: e_1_2_14_20_1
  doi: 10.1074/jbc.M109861200
– ident: e_1_2_14_21_1
  doi: 10.1042/bj20021321
– ident: e_1_2_14_24_1
  doi: 10.1038/s41580-018-0076-0
– ident: e_1_2_14_179_1
  doi: 10.1016/B978-0-12-394387-3.00002-1
– ident: e_1_2_14_29_1
  doi: 10.1074/jbc.M104935200
– ident: e_1_2_14_113_1
  doi: 10.1186/s13045-016-0266-1
– ident: e_1_2_14_36_1
  doi: 10.1021/acschembio.7b00942
– ident: e_1_2_14_17_1
  doi: 10.1016/j.jmb.2004.02.006
– ident: e_1_2_14_174_1
  doi: 10.1002/ijc.2910490113
– ident: e_1_2_14_61_1
  doi: 10.1038/nature07925
– ident: e_1_2_14_80_1
– start-page: 724187
  year: 2019
  ident: e_1_2_14_139_1
  article-title: Correction of Niemann‐Pick type C1 disease with the histone deacetylase inhibitor valproic acid
  publication-title: bioRxiv
– ident: e_1_2_14_70_1
  doi: 10.1016/S0021-9258(17)44885-X
– ident: e_1_2_14_96_1
  doi: 10.2340/00015555-1886
– ident: e_1_2_14_78_1
  doi: 10.1093/bioinformatics/btu033
– ident: e_1_2_14_172_1
  doi: 10.1056/NEJMoa1916945
– ident: e_1_2_14_39_1
  doi: 10.1073/pnas.0706487104
– ident: e_1_2_14_183_1
– ident: e_1_2_14_9_1
  doi: 10.1021/acs.chemrev.7b00181
– ident: e_1_2_14_129_1
  doi: 10.1007/s00280-011-1693-x
– ident: e_1_2_14_97_1
  doi: 10.3109/10428194.2012.656625
– ident: e_1_2_14_161_1
– ident: e_1_2_14_33_1
  doi: 10.1038/ncomms15368
– ident: e_1_2_14_53_1
  doi: 10.1016/j.bbagrm.2017.12.002
– volume: 47
  start-page: W5
  issue: 1
  year: 2019
  ident: e_1_2_14_77_1
  article-title: MAFFT‐DASH: integrated protein sequence and structural alignment
  publication-title: Nucleic Acids Res
– ident: e_1_2_14_103_1
  doi: 10.1002/hon.2691
– ident: e_1_2_14_145_1
  doi: 10.1172/JCI92684
– ident: e_1_2_14_5_1
  doi: 10.1080/17460441.2017.1295954
– ident: e_1_2_14_13_1
  doi: 10.1146/annurev-pharmtox-011613-135943
– ident: e_1_2_14_34_1
  doi: 10.1021/acs.biochem.8b00079
– ident: e_1_2_14_48_1
  doi: 10.1074/jbc.M110.146860
– ident: e_1_2_14_8_1
  doi: 10.1038/s41580-018-0081-3
– ident: e_1_2_14_69_1
  doi: 10.1056/NEJMoa041892
– ident: e_1_2_14_88_1
  doi: 10.1016/j.ejmech.2016.05.047
– ident: e_1_2_14_11_1
  doi: 10.1021/acs.jmedchem.0c00830
– ident: e_1_2_14_109_1
  doi: 10.1182/blood-2013-12-516245
– ident: e_1_2_14_171_1
  doi: 10.1215/S1152851704000183
– ident: e_1_2_14_163_1
  doi: 10.1124/jpet.117.244939
– ident: e_1_2_14_82_1
  doi: 10.1093/nar/gkx1037
– ident: e_1_2_14_134_1
  doi: 10.1007/s00277-013-1910-2
– ident: e_1_2_14_37_1
  doi: 10.1016/j.chembiol.2018.04.007
– ident: e_1_2_14_65_1
  doi: 10.2337/db11-0440
– ident: e_1_2_14_132_1
  doi: 10.3109/10428194.2012.664844
– ident: e_1_2_14_168_1
  doi: 10.1007/s13277-015-3781-8
– ident: e_1_2_14_16_1
  doi: 10.1101/cshperspect.a018713
– ident: e_1_2_14_169_1
  doi: 10.1111/j.1474-9726.2011.00680.x
– ident: e_1_2_14_124_1
  doi: 10.1186/s13045-017-0439-6
– ident: e_1_2_14_122_1
  doi: 10.1093/annonc/mdv237
– ident: e_1_2_14_2_1
  doi: 10.1038/nbt.1678
– ident: e_1_2_14_10_1
  doi: 10.1038/nrd4360
– ident: e_1_2_14_116_1
  doi: 10.1159/000498905
– ident: e_1_2_14_156_1
  doi: 10.1093/nar/gkw107
– ident: e_1_2_14_60_1
  doi: 10.1016/j.ccr.2010.10.022
– ident: e_1_2_14_120_1
  doi: 10.1111/bjh.13222
– ident: e_1_2_14_90_1
  doi: 10.1182/blood-2018-11-881268
– ident: e_1_2_14_41_1
  doi: 10.1387/ijdb.082649rb
– ident: e_1_2_14_130_1
  doi: 10.1016/S2352-3026(16)30165-X
– ident: e_1_2_14_14_1
  doi: 10.1038/nrd3478
– ident: e_1_2_14_119_1
  doi: 10.1200/JCO.2014.59.2782
– ident: e_1_2_14_112_1
  doi: 10.1016/S2352-3026(15)00023-X
– ident: e_1_2_14_95_1
  doi: 10.1097/FPC.0b013e32834a8639
– ident: e_1_2_14_153_1
  doi: 10.1016/j.nmd.2016.07.002
– ident: e_1_2_14_166_1
  doi: 10.1111/cen.13154
– ident: e_1_2_14_143_1
  doi: 10.1371/journal.ppat.1005142
– ident: e_1_2_14_49_1
  doi: 10.1074/jbc.M114.596247
– ident: e_1_2_14_106_1
  doi: 10.1080/10428194.2016.1247956
– ident: e_1_2_14_25_1
  doi: 10.1016/j.tips.2015.04.013
– ident: e_1_2_14_83_1
– ident: e_1_2_14_42_1
  doi: 10.1038/nn.2333
– ident: e_1_2_14_40_1
  doi: 10.1016/bs.acr.2018.02.006
– ident: e_1_2_14_56_1
  doi: 10.2183/pjab.93.019
– ident: e_1_2_14_15_1
  doi: 10.1093/nar/25.18.3693
– ident: e_1_2_14_89_1
  doi: 10.1093/nar/gky1033
– ident: e_1_2_14_149_1
  doi: 10.1200/JCO.2019.37.15_suppl.7551
– ident: e_1_2_14_26_1
  doi: 10.1021/acschembio.6b00396
– ident: e_1_2_14_84_1
– ident: e_1_2_14_127_1
  doi: 10.1016/S1470-2045(14)70440-1
– ident: e_1_2_14_81_1
– ident: e_1_2_14_92_1
  doi: 10.1200/JCO.2006.10.2434
– ident: e_1_2_14_157_1
  doi: 10.1002/ana.24249
– ident: e_1_2_14_50_1
  doi: 10.1016/S0092-8674(02)00861-9
– ident: e_1_2_14_131_1
  doi: 10.1016/S2352-3026(18)30174-1
– ident: e_1_2_14_164_1
  doi: 10.1182/bloodadvances.2018019240
– ident: e_1_2_14_44_1
  doi: 10.1172/jci.insight.97903
– ident: e_1_2_14_118_1
  doi: 10.1182/blood.2019001285
– ident: e_1_2_14_176_1
  doi: 10.1016/j.lungcan.2004.03.002
– ident: e_1_2_14_27_1
  doi: 10.1073/pnas.96.9.4868
– ident: e_1_2_14_66_1
  doi: 10.1111/dom.12470
– ident: e_1_2_14_135_1
  doi: 10.1038/s41408-018-0154-8
– ident: e_1_2_14_123_1
  doi: 10.5582/irdr.2016.01024
– ident: e_1_2_14_150_1
  doi: 10.1182/blood-2011-06-362434
– ident: e_1_2_14_3_1
  doi: 10.1038/nbt.1685
– ident: e_1_2_14_170_1
  doi: 10.2217/epi-2016-0160
– ident: e_1_2_14_18_1
  doi: 10.1038/nrg2485
– ident: e_1_2_14_141_1
  doi: 10.1074/jbc.M114.605428
– ident: e_1_2_14_165_1
  doi: 10.1080/13543784.2017.1291630
– ident: e_1_2_14_177_1
  doi: 10.1200/jco.2004.22.90140.7279
– ident: e_1_2_14_133_1
  doi: 10.1080/10428194.2017.1372575
– ident: e_1_2_14_67_1
  doi: 10.1016/j.cell.2011.03.043
– ident: e_1_2_14_144_1
  doi: 10.1016/S2352-3018(16)30055-8
– ident: e_1_2_14_85_1
– ident: e_1_2_14_128_1
  doi: 10.1182/blood-2015-09-665018
– ident: e_1_2_14_152_1
  doi: 10.1158/1078-0432.CCR-17-1178
– ident: e_1_2_14_178_1
  doi: 10.1007/s40264-018-0773-9
– ident: e_1_2_14_184_1
– volume: 8
  start-page: 2142
  issue: 7
  year: 2002
  ident: e_1_2_14_175_1
  article-title: A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies
  publication-title: Clin Cancer Res
– ident: e_1_2_14_47_1
  doi: 10.1172/JCI133753
– ident: e_1_2_14_32_1
  doi: 10.1186/s13045-018-0654-9
– ident: e_1_2_14_22_1
  doi: 10.1016/S0002-9440(10)63320-2
– ident: e_1_2_14_46_1
  doi: 10.3390/ijms20071605
– ident: e_1_2_14_31_1
  doi: 10.1074/jbc.M108931200
– ident: e_1_2_14_91_1
  doi: 10.1002/ajh.25577
– ident: e_1_2_14_181_1
  doi: 10.1021/acs.jmedchem.8b01597
– ident: e_1_2_14_107_1
  doi: 10.1080/09546634.2017.1412064
– ident: e_1_2_14_23_1
  doi: 10.1042/BST20130010
– ident: e_1_2_14_72_1
  doi: 10.1021/jm0303094
– ident: e_1_2_14_51_1
  doi: 10.1038/s41588-019-0514-8
– ident: e_1_2_14_57_1
  doi: 10.1182/blood-2012-07-441949
– ident: e_1_2_14_28_1
  doi: 10.1016/S1074-7613(03)00109-2
– ident: e_1_2_14_114_1
  doi: 10.1182/blood-2017-09-806737
– ident: e_1_2_14_12_1
  doi: 10.1016/j.tips.2018.03.003
– ident: e_1_2_14_99_1
  doi: 10.1200/JCO.2008.21.6150
– ident: e_1_2_14_62_1
  doi: 10.1186/1750-1326-8-7
– ident: e_1_2_14_105_1
  doi: 10.1158/1078-0432.CCR-19-2152
– ident: e_1_2_14_121_1
  doi: 10.1002/jcph.625
– ident: e_1_2_14_58_1
  doi: 10.1182/blood-2012-08-450916
– ident: e_1_2_14_154_1
  doi: 10.1002/art.30238
– ident: e_1_2_14_52_1
  doi: 10.3390/cells4020135
– ident: e_1_2_14_148_1
  doi: 10.1016/S0092-8674(03)00939-5
– ident: e_1_2_14_75_1
  doi: 10.1074/jbc.M807045200
– ident: e_1_2_14_138_1
  doi: 10.1016/S1470-2045(19)30164-0
– ident: e_1_2_14_182_1
  doi: 10.1016/S1470-2045(19)30279-7
– ident: e_1_2_14_162_1
– ident: e_1_2_14_35_1
  doi: 10.1074/jbc.M111871200
– ident: e_1_2_14_159_1
  doi: 10.1186/s40673-017-0062-x
– ident: e_1_2_14_167_1
  doi: 10.1186/s12885-016-2957-y
– volume: 40
  start-page: 667
  issue: 9
  year: 2017
  ident: e_1_2_14_55_1
  article-title: HDAC11 inhibits myoblast differentiation through repression of MyoD‐dependent transcription
  publication-title: Mol Cells
  doi: 10.14348/molcells.2017.0116
– ident: e_1_2_14_104_1
  doi: 10.1001/jamaoncol.2016.0004
– ident: e_1_2_14_137_1
  doi: 10.3109/10428194.2012.661175
– ident: e_1_2_14_43_1
  doi: 10.1101/gad.1809209
– ident: e_1_2_14_110_1
  doi: 10.1200/JCO.2011.37.4223
– ident: e_1_2_14_125_1
  doi: 10.1038/nrdp.2017.46
SSID ssj0013165
Score 2.6910355
SecondaryResourceType review_article
Snippet The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During...
SourceID swepub
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 4577
SubjectTerms Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
belinostat
epigenetics
HDAC inhibition
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylase Inhibitors - therapeutic use
HIV Infections - drug therapy
Humans
panobinostat
romidepsin
vorinostat
Title Recent developments of HDAC inhibitors: Emerging indications and novel molecules
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbcp.14889
https://www.ncbi.nlm.nih.gov/pubmed/33971031
https://www.proquest.com/docview/2525663535
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-469673
Volume 87
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RTlzaAn1sH8hULeqBIK3jvNrTsoBWlVpFFVQcKlkex4EVbYLI5gC_vjN5bWmphJpcIsWOHI_H89me-QbgrYzQ2oiWqYh57CmrnIe03vHQz2RiciQLylsDn7-EsxP16TQ4XYGPfSxMyw8xbLixZjTzNSu4weo3JUd7SWoexxy8x75aDIi-yuUJwrhJI8mQmBZbwbhjFWIvnqHmbVv0F8Ac2ENvA9fG8hw9gu99m1uHk4u9eoF79uYPOsf__KnH8LBDpGLSDqF1WHHFBuykLaX19a44XkZoVbtiR6RLsuvrTUgJd5LdEtnS-agSZS5mB5OpmBfnc5xzPp8Pgne_OCGS4EPybp9QmCITRUk1xc82Ta-rnsDJ0eHxdOZ1WRo8qwjeeInME6ti4-d0R2hI-FEgQ6QrSXIbGFQhxiofB5YDHpTMXYbSGDKNQWJs5j-F1aIs3HMQVskoYsyHMSozDmOnLAa-pDnGxVRvBO97eWnbUZhzJo0ful_KUP_ppv9G8GYoetnydtxVaLsXuiat4qMSU7iyrrSkIcNYzA9G8KwdDcNnfIJwnBxjBO_a4TG8Yarug_m3iS6vznRdaxUmYeRTqxuR_7sden-aNg8v7l_0JaxJdq9pPGteweriqnavCR8tcAseSJVuNerwC7UoDUA
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VcoAL78fyNAgqDk2ldZwX4rJsqRZoqxXaol4qy-M4dFVIqu7mUH49M85jKQ8JkVwixY4c2-P5Zjz-BuCFTNDahMxUxCINlFUuQLJ3AgxzmZkCSYOya2BvP54cqA-H0eEavOnOwjT8EL3DjSXDr9cs4OyQ_knK0Z6SnKdpdgkuc0Zvb1B9kqs9hKFPJMmgmMytaNjyCnEcT1_1ojb6DWL2_KEXoavXPTvX4ahrdRNycrJVL3HLfv-F0PF_f-sGXGtBqRg1s-gmrLnyFmxMG1br800xWx3SWmyKDTFd8V2f34YpQU9SXSJfxR8tRFWIyfZoLObl8RznnNLntWAHGOdEErxP3roKhSlzUVZUU3xrMvW6xR042Hk3G0-CNlFDYBUhnCCTRWZVasKC7gQNjX8SyRjpyrLCRgZVjKkqhpHlMw9KFi5HaQxpxygzNg_vwnpZle4-CKtkkjDswxSVGcapUxajUNIy41KqN4BX3YBp27KYczKNr7qzZqj_tO-_ATzvi5421B1_KvSsG3VNgsW7JaZ0Vb3QkuYMw7EwGsC9Zjr0nwkJxXF-jAG8bOZH_4bZurfnn0e6Ovui61qrOIuTkFrtx_zv7dBvx1P_8ODfiz6FK5PZ3q7efb__8SFclRxt4wNtHsH68qx2jwkuLfGJl4ofG0AQhA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIiEutLyXFjAIKg5NxTpO4sBp2WW1vKoItagHJMvj2LACklV3cyi_nnFeS3lIiOQSKXbk2DOeb-zxNwCPeILGJOSmIjoZCCNsgOTvBBjmPNUOyYL6pYF3h_HsWLw-iU424Hl3Fqbhh-gX3Lxm1PO1V_BF7n5ScjQLUnMp0wtwUcRPpRfpyXu-3kIY1nkkPSYmbysatrRCPoynr3reGP2GMHv60PPItTY90y342DW6iTj5clCt8MB8_4XP8T__ahuutJCUjRoZugobtrgGe1nDaX22z47WR7SW-2yPZWu267PrkBHwJMPF8nX00ZKVjs0mozGbF5_nOPcJfZ4xv_zlMyIxv0veLhQyXeSsKKkm-9bk6bXLG3A8fXk0ngVtmobACMI3QcpdaoTUoaM7QU2jn0Q8RrrS1JlIo4hRCjeMjD_xILizOXKtyTZGqTZ5eBM2i7Kwt4EZwZPEgz6UKPQwllYYjEJOk4yVVG8AT7rxUqblMPepNL6qzpeh_lN1_w3gYV900RB3_KnQg27QFamV3yvRhS2rpeIkMh6MhdEAbjXS0H8mJAzns2MM4HEjHv0bz9U9mX8YqfL0k6oqJeI0TkJqdT3kf2-HejHO6oc7_170PlzKJlP19tXhmx24zH2oTR1lswubq9PK3iWstMJ7tU78AACvDzw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+developments+of+HDAC+inhibitors%3A+Emerging+indications+and+novel+molecules&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Bondarev%2C+Andrey+D&rft.au=Attwood%2C+Misty+M&rft.au=Jonsson%2C+J%C3%B6rgen&rft.au=Chubarev%2C+Vladimir+N&rft.date=2021-12-01&rft.eissn=1365-2125&rft.volume=87&rft.issue=12&rft.spage=4577&rft_id=info:doi/10.1111%2Fbcp.14889&rft_id=info%3Apmid%2F33971031&rft.externalDocID=33971031
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon